Research programme: osteoarthritis therapeutics - Galapagos/GlaxoSmithKline

Drug Profile

Research programme: osteoarthritis therapeutics - Galapagos/GlaxoSmithKline

Alternative Names: GT-448; GT-622; GT-745

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Galapagos NV
  • Class Small molecules
  • Mechanism of Action Protein kinase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Osteoarthritis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Osteoarthritis in Belgium
  • 19 Apr 2011 Preclinical development is ongoing in Belgium
  • 18 Dec 2009 GlaxoSmithKline and Galapagos have further expanded their research alliance
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top